Dabrafenib/Trametinib for BRAF V600E Mutation-Positive Advanced NSCLC (BMIC-018)

Dabrafenib/Trametinib for BRAF V600E Mutation-Positive Advanced NSCLC (BMIC-018)

Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as published by Blanchard & colleagues in Lancet Oncology. Visit http://BeaconMedIC.com for more media & information.